"ADP-ribosyl Cyclase 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A bifunctional enzyme that catalyzes the synthesis and HYDROLYSIS of CYCLIC ADP-RIBOSE (cADPR) from NAD+ to ADP-RIBOSE. It is a cell surface molecule which is predominantly expressed on LYMPHOID CELLS and MYELOID CELLS.
| Descriptor ID |
D051997
|
| MeSH Number(s) |
D08.811.277.450.430.400.060.500 D12.776.543.550.045
|
| Concept/Terms |
ADP-ribosyl Cyclase 1- ADP-ribosyl Cyclase 1
- 1, ADP-ribosyl Cyclase
- ADP ribosyl Cyclase 1
- Cyclase 1, ADP-ribosyl
- T10 Antigen
- Antigen, T10
- NIM-R5 Antigen
- NIM R5 Antigen
- CD38 Antigens
- ADPR Cyclase T10
- Cyclase T10, ADPR
- Acute Lymphoblastic Leukemia Cells Antigen CD38
- Lymphocyte Differentiation Antigen CD38
- Antigens, CD38
- CD38 Antigen
- ADPR Cyclase CD38
- CD38, ADPR Cyclase
- Cyclase CD38, ADPR
|
Below are MeSH descriptors whose meaning is more general than "ADP-ribosyl Cyclase 1".
Below are MeSH descriptors whose meaning is more specific than "ADP-ribosyl Cyclase 1".
This graph shows the total number of publications written about "ADP-ribosyl Cyclase 1" by people in this website by year, and whether "ADP-ribosyl Cyclase 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 2 | 2 |
| 2007 | 0 | 1 | 1 |
| 2012 | 1 | 2 | 3 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 1 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "ADP-ribosyl Cyclase 1" by people in Profiles.
-
Overcoming CD226-related immune evasion in acute myeloid leukemia with CD38 CAR-engineered NK cells. Cell Rep. 2025 Jan 28; 44(1):115122.
-
A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer. Cancer Res Commun. 2024 09 01; 4(9):2444-2453.
-
IFN-? and CD38 in AML: a T-cell engagement made in heaven? Blood. 2024 04 18; 143(16):1556-1557.
-
Preclinical characterization of ISB 1342, a CD38?? CD3 T-cell engager for relapsed/refractory multiple?myeloma. Blood. 2023 07 20; 142(3):260-273.
-
Effect of anti-CD38 monoclonal antibodies on hepatitis C virus replication in chronically infected patients with multiple myeloma: a prospective series. Leuk Lymphoma. 2023 04; 64(4):900-903.
-
Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series. Hematology. 2022 Dec; 27(1):204-207.
-
Expanding anti-CD38 immunotherapy for lymphoid malignancies. J Exp Clin Cancer Res. 2022 Jun 28; 41(1):210.
-
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. Am J Hematol. 2022 07; 97(7):E276-E280.
-
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study. J Immunother Cancer. 2022 01; 10(1).
-
T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis. Blood. 2021 04 29; 137(17):2337-2346.